Comparison of plasma lipoprotein profiles and malondialdehyde between hyperlipidemia dogs with/without treatment

BMC Veterinary Research

Nobuko Mori¹  Toshiro Arai¹  Ichiro Yamamoto¹  Shingo Ishikawa¹  Yuki Okada¹  Koh Kawasumi¹  Gebin Li¹ 

[1] Department of Veterinary Bioscience, School of Veterinary Medicine, Nippon Veterinary and Life Science University, 1-7-1 Kyonancho, Musashino, Tokyo 180-8602, Japan

关键词: Screening criteria;    Prevention;    Malondialdehyde;    Lipid profiles;    Hyperlipidemia;    Dog;   

Others  :  1119303
DOI  :  10.1186/1746-6148-10-67

 received in 2013-09-18, accepted in 2014-03-05,  发布年份 2014

【 摘 要 】

Background

The aim of this study is to compare metabolic parameters, malondialdehyde as a lipid oxidation marker, and lipid profiles between dogs with untreated hyperlipidemia and hyperlipidemia with treatment, in order to examine the usefulness of malondialdehyde and lipid profiles as diagnostic parameters at early stages of hyperlipidemia.

Results

Dog samples were collected from four different veterinary clinics across Japan from March to June 2013. They were separated into three groups: control, untreated hyperlipidemia based on temporally screening, and hyperlipidemia with current anti-hyperlipidemic (statins and fibrates) treatment. Triglyceride levels of untreated hyperlipidemia dogs were significantly higher than those of control dogs. ALT levels of hyperlipidemic dogs with treatment were the highest among three groups. VLDL and LDL of both cholesterol and triglyceride of untreated hyperlipidemia dogs were the highest among three groups. HDL₁ levels in triglyceride of hyperlipidemia dogs with treatment were significantly higher than those of control and untreated hyperlipidemia dog. Malondialdehyde concentrations of untreated hyperlipidemia dogs were significantly higher than those of control and hyperlipidemic dogs with treatment.

Conclusions

In this study, dogs with untreated hyperlipidemia clearly showed abnormal lipid status, whereas hyperlipidemic dogs under anti-hyperlipidemia treatment showed more normal lipid status suggesting the effectiveness of the therapy. Anti-hyperlipidemics (statins and fibrates) for dogs are also effective in relieving elevated levels of lipids and lipid oxidation. Plasma lipid (triglyceride and cholesterol) profiles and malondialdehyde are useful diagnostic tools for identifying early stages of untreatment hyperlipidemia in dogs.

【 授权许可】

   
2014 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Bauer JE: Lipoprotein-mediated transport of dietary and synthesized lipids and lipid abnormalities of dogs and cats. J Am Vet Med Assoc 2004, 224:668-675.
• [2]Fleeman L: Is hyperlipidemia clinically important in dogs? Vet J 2010, 183:10.
• [3]Xenoulis PG, Steiner JM: Lipid metabolism and hyperlipidemia in dogs. Vet J 2010, 183:12-21.
• [4]Kawasumi K, Suzuki T, Fujiwara M, Mori N, Yamamoto I, Arai T: New criteria of hyperlipidemia with insulin resistance in dogs. J Anim Vet Adv 2012, 11:3950-3952.
• [5]Mori N, Lee P, Kondo K, Kido T, Saito T, Arai T: Potential use of cholesterol lipoprotein profile to confirm obesity status in dogs. Vet Res Commun 2011, 35:223-235.
• [6]Moussa SA: Oxidative stress in diabetes mellitus. Rom J Biophys 2008, 18:225-236.
• [7]Terpstra AH, Sanchez-Muniz FJ, West CE, Woodward CJ: The density profile and cholesterol concentration of serum lipoproteins in domestic and laboratory animals. Comp Biochem Physiol B 1982, 71:669-673.
• [8]Whitney MS: Evaluation of hyperlipidemias in dogs and cats. Semin Vet Med Surg (Small Anim) 1992, 7:292-300.
• [9]Mori N, Lee P, Muranaka S, Sagara F, Takemitsu H, Nishiyama Y, Yamamoto I, Yagishita M, Arai T: Predisposition for primary hyperlipidemia in miniature schnauzers and Shetland sheepdogs as compared to other canine breeds. Res Vet Sci 2010, 88:394-399.
• [10]Brunzell JD, Bierman EL: Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia. Med Clin North Am 1982, 66:455-468.
• [11]Bilheimer DW, Grundy SM, Brown MS, Goldstein JL: Mevinolin stimulates receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Trans Assoc Am Physicians 1983, 96:1-9.
• [12]Tamura A, Watanabe T, Nasu M: Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients. Circ J 2003, 10:816-820.
• [13]Kondo A, Manabe M, Saito K, Maekawa M, Kanno T: Insulin treatment prevents LDL from accelerated oxidation in patients with diabetes. J Atheroscler Thromb 2002, 9:280-7.
• [14]Kanno T, Maekawa M: Influence of fibrate treatment on malondialdehyde-modified LDL concentration. Clin Chim Acta 2004, 339:97-103.
• [15]Xenoulis PG, Cammarata PJ, Walzem RL, Macfarlane RD, Suchodolski JS, Steiner JM: Novel lipoprotein density profiling in healthy dogs of various breeds, healthy miniature schnauzers, and miniature schnauzers with hyperlipidemia. BMC Vet Res 2013, 9:47. BioMed Central Full Text